Download PDF
CC BY 4.0 · Journal of Coloproctology 2025; 45(02): s00451809677
DOI: 10.1055/s-0045-1809677
Original Article

Outcome of Cytoreductive Surgery with HIPEC in Ovarian Versus Gastrointestinal Peritoneal Carcinomatosis: A 7-Year Single Centre Experience

Mohamed E Ramadan
1   Department of General Surgery, Faculty of Medicine, Benha University, Egypt
,
Emad M Abdelrahman 
1   Department of General Surgery, Faculty of Medicine, Benha University, Egypt
,
Youssef Abdel Zaher
2   Department of Obstetrics and Gynecology, Faculty of Medicine, Benha University, Egypt
,
Ahmed M Abostate
1   Department of General Surgery, Faculty of Medicine, Benha University, Egypt
› Author Affiliations
Funding The author(s) received no financial support for the research.
› Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction

The use of Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat peritoneal carcinomatosis (PC) has grown in popularity in recent years. The aim of the study was to report our own experience concerning morbidities, complications, and survival outcomes in CRS and HIPEC in tumors of gastrointestinal vs ovarian origin.

Patients and Methods

The current study included 62 patients who were admitted by peritoneal Carcinomatosis and eligible for CRS and HIPEC. Follow-up was planned for 5 years.

Results

The age of eligible patients was 40.6 ± 3.9 and 39.2 ± 4.6 years in patients with gastrointestinal PC and those with OC respectively. The reported mean Peritoneal Carcinomatosis Index (PCI) was less in Group B (p = 0.056). There was no reported significant difference between both groups regarding intra-hospital mortality, postoperative complication rate, rate of reintervention, or even the length of hospital stays. However, the ICU stay was significantly less in Patients with Ovarian Cancer (OC). The mean Overall Survival (OS) was 31.2 ± 6.2 and 39.1 ± 4.22 in groups A and B respectively with significantly more OS and Disease-free Survival (DFS) reported in Group B (P = 0.046*). The reported 5-year Survival was insignificantly different between both Groups.

Conclusion

In certain patient groups with PC from gastrointestinal and Ovarian malignancies, CRS + HIPEC could produce long-term OS with tolerable morbidity and mortality with better outcome OS and DFS in patients with OC.

Keywords

Peritoneal Carcinomatosis - Peritoneal Carcinomatosis Index - Cytoreductive surgery - Hyperthermic Intraperitoneal Chemotherapy. Overall Survival - Disease Free Survival

Author Contributions

Study conception and design were carried out by Emad M. Abdelrahman and Yousef Abdelzaher. Data acquisition was performed by Mohamed E. Ramadan and Ahmed M. Abostate. Analysis and interpretation of the data were conducted by Yousef Abdelzaher and Mohamed E. Ramadan. The manuscript was drafted by Emad M. Abdelrahman and Mohamed E. Ramadan. Critical revision of the manuscript was undertaken by Emad M. Abdelrahman, Yousef Abdelzaher, Mohamed E. Ramadan, and Ahmed M. Abostate. This form is submitted with the manuscript by Emad M. Abdelrahman.




Publication History

Received: 10 January 2025

Accepted: 21 March 2025

Article published online:
20 June 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Mohamed E Ramadan, Emad M Abdelrahman, Youssef Abdel Zaher, Ahmed M Abostate. Outcome of Cytoreductive Surgery with HIPEC in Ovarian Versus Gastrointestinal Peritoneal Carcinomatosis: A 7-Year Single Centre Experience. Journal of Coloproctology 2025; 45: s00451809677.
DOI: 10.1055/s-0045-1809677
 

  • References

  • 1 Nassabein R, Younan R, Loungarath R. et al. A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies. Can J Surg 2022; 65 (03) E342-E351
    CrossrefPubMedSearch in Google Scholar
  • 2 Montori G, Coccolini F, Fugazzola P. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience. J Gastrointest Oncol 2018; 9 (02) 241-253 10.21037/jgo.2017.12.04
    PubMedSearch in Google Scholar
  • 3 Carboni F, Federici O, Sperduti I. et al. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience. Cancers (Basel) 2021; 13 (03) 523 10.3390/cancers13030523
    PubMedSearch in Google Scholar
  • 4 Narod S. Can advanced-stage ovarian cancer be cured?. Nat Rev Clin Oncol 2016; 13 (04) 255-261 10.1038/nrclinonc.2015.224
    PubMedSearch in Google Scholar
  • 5 Revaux A, Carbonnel M, Kanso F. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update. Horm Mol Biol Clin Investig 2020; 41 (03)
    CrossrefPubMedSearch in Google Scholar
  • 6 de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 2013; 39 (04) 321-327 10.1016/j.ctrv.2012.11.003
    CrossrefPubMedSearch in Google Scholar
  • 7 Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer J 2009; 15 (03) 225-235 10.1097/PPO.0b013e3181a9c781
    PubMedSearch in Google Scholar
  • 8 Carr NJ, Cecil TD, Mohamed F. et al; Peritoneal Surface Oncology Group International. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016; 40 (01) 14-26
    CrossrefPubMedSearch in Google Scholar
  • 9 Bradley RF, Stewart IV JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006; 30 (05) 551-559 10.1097/01.pas.0000202039.74837.7d
    PubMedSearch in Google Scholar
  • 10 Chua TC, Moran BJ, Sugarbaker PH. et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30 (20) 2449-2456
    CrossrefPubMedSearch in Google Scholar
  • 11 Neeman E, Gresham G, Ovasapians N. et al. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. Oncologist 2019; 24 (12) e1460-e1466 10.1634/theoncologist.2018-0882
    PubMedSearch in Google Scholar
  • 12 Ye Z, Yu P, Cao Y. et al. Prediction of Peritoneal Cancer Index and Prognosis in Peritoneal Metastasis of Gastric Cancer Using NLR-PLR-DDI Score: A Retrospective Study. Cancer Manag Res 2022; 14 (14) 177-187 10.2147/CMAR.S343467
    PubMedSearch in Google Scholar
  • 13 Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003; 12 (03) 703-727, xiii 10.1016/s1055-3207(03)00048-6
    PubMedSearch in Google Scholar
  • 14 Framarini M, D'Acapito F, Di Pietrantonio D. et al. Cytoreduction Plus Hyperthermic Intraperitoneal Chemotherapy in Primary and Recurrent Ovarian Cancer: A Single-Center Cohort Study. Surgeries 2023; 4: 590-599 10.3390/ surgeries4040057
    Search in Google Scholar
  • 15 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249 10.3322/caac.21660
    CrossrefPubMedSearch in Google Scholar
  • 16 Graf W, Ghanipour L, Birgisson H, Cashin PH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal Cancer-An Overview of Current Status and Future Perspectives. Cancers (Basel) 2024; 16 (02) 284
    CrossrefPubMedSearch in Google Scholar
  • 17 Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015; 17 (09) 772-778 10.1111/codi.12975
    PubMedSearch in Google Scholar
  • 18 Wang TY, Chen CY, Lu CH. et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia. Int J Hyperthermia 2018; 34 (03) 328-335 10.1080/02656736.2017.1337238
    PubMedSearch in Google Scholar
  • 19 van Driel WJ, Koole SN, Sikorska K. et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med 2018; 378 (03) 230-240
    CrossrefPubMedSearch in Google Scholar
  • 20 Mirnezami R, Mehta AM, Chandrakumaran K. et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 2014; 111 (08) 1500-1508
    CrossrefPubMedSearch in Google Scholar
  • 21 Shaib WL, Assi R, Shamseddine A. et al. Appendiceal Mucinous Neoplasms: Diagnosis and Management. Oncologist 2017; 22 (09) 1107-1116 Erratum in: Oncologist. 2018, 23(1):137. doi: 10.1634/theoncologist.2017-0081erratum
    CrossrefPubMedSearch in Google Scholar
  • 22 Waite K, Youssef H. The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review. Ann Surg Oncol 2017; 24 (03) 705-720 10.1245/s10434-016-5712-3
    CrossrefPubMedSearch in Google Scholar
  • 23 Goéré D, Passot G, Gelli M. et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia 2017; 33 (05) 520-527 10.1080/02656736.2017.1301576
    CrossrefPubMedSearch in Google Scholar
  • 24 Klaver CE, Musters GD, Bemelman WA. et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 2015; 15: 428
    CrossrefPubMedSearch in Google Scholar
  • 25 Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 2013; 20 (01) 183-192 10.1245/s10434-012-2473-5
    PubMedSearch in Google Scholar
  • 26 Enblad M, Graf W, Birgisson H. Risk factors for appendiceal and colorectal peritoneal metastases. Eur J Surg Oncol 2018; 44 (07) 997-1005 10.1016/j.ejso.2018.02.245
    PubMedSearch in Google Scholar
  • 27 Arrizabalaga NB, Navascués JME, Echaniz GE. et al. Prophylactic HIPEC in pT4 Colon Tumors: Proactive Approach or Overtreatment?. Ann Surg Oncol 2020; 27 (04) 1094-1100 10.1245/s10434-019-07970-z
    PubMedSearch in Google Scholar
  • 28 Arjona-Sánchez A, Espinosa-Redondo E, Gutiérrez-Calvo A. et al; Grupo Español de Carcinomatosis Peritoneal. Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial. JAMA Surg 2023; 158 (07) 683-691 10.1001/jamasurg.2023.0662
    PubMedSearch in Google Scholar
  • 29 Klaver CEL, Wisselink DD, Punt CJA. et al; COLOPEC collaborators group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 2019; 4 (10) 761-770 10.1016/S2468-1253(19)30239-0
    CrossrefPubMedSearch in Google Scholar
  • 30 Goéré D, Glehen O, Quenet F. et al; BIG-RENAPE group. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol 2020; 21 (09) 1147-1154 10.1016/S1470-2045(20)30322-3
    CrossrefPubMedSearch in Google Scholar